Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 4, 2006, Pages 1268-1274

  Rauch, Frank ^a,b   Munns, Craig ^a   Land, Christof ^a   Glorieux, Francis H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE GROWTH; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FRACTURE; FUNCTIONAL STATUS; HUMAN; INCIDENCE; MALE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; ADULT; BONE; CHILD; CLINICAL TRIAL; FOLLOW UP; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PRESCHOOL CHILD; RADIOGRAPHY; SPINE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; SPINE;

EID: 33646025276     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2413     Document Type: Article

References (19)

1. Rauch F, Glorieux FH 2004 Osteogenesis imperfecta. Lancet 363:1377-1385
2. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707
3. Rodan G, Reszka A, Golub E, Rizzoli R 2004 Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291-1300
4. Rauch F, Plotkin H, Zeitlin L, Glorieux FH 2003 Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610-614
5. Rauch F, Travers R, Plotkin H, Glorieux FH 2002 The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110:1293-1299
6. Rauch F, Travers R, Glorieux FH 2006 Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 91:511-516
7. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH 2004 Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779-1786
8. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
9. Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH 2000 Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85:1846-1850
10. Zeitlin L, Fassier F, Glorieux FH 2003 Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 12:77-87
11. Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL 2002 Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45-60
12. Feldman AB, Haley SM, Coryell J 1990 Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 70:602-610
13. Glastre C, Braillon P, David L, Cochat P, Meunier PJ, Delmas PD 1990 Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 70:1330-1333
14. Southard RN, Morris JD, Mahan JD, Hayes JR, Torch MA, Sommer A, Zipf WB 1991 Bone mass in healthy children: measurement with quantitative DXA. Radiology 179:735-738
15. Carter DR, Bouxsein ML, Marcus R 1992 New approaches for interpreting projected bone densitometry data. J Bone Miner Res 7:137-145
16. D'Amour P, Labelle F, Lecavalier L, Plourde V, Harvey D 1986 Influence of serum Ca concentration on circulating molecular forms of PTH in three species. Am J Physiol 251:E680-E687
17. Bollen AM, Eyre DR 1994 Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 15:31-34
18. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
19. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM 2004 Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259-1269